Pharming Group lowers revenue guidance following consecutive quarterly declines in Ruconest sales

Pharming Group has revised its revenue forecast downward after reporting a second consecutive quarter of declining sales for its primary product, Ruconest. The persistence of this downward trend suggests structural challenges in the drug's market performance, though the specific drivers behind the decline remain unelaborated.